Sign In
Buy ASH
$57.00
-0.580 (-1.01%)
At Close: Jun 03, 2026
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
07:00am, Wednesday, 13'th Nov 2024
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
Ashland's Earnings Miss in Q4, Revenues Surpass Estimates
04:01pm, Tuesday, 12'th Nov 2024
ASH sees higher sales volumes in Personal Care, Specialty Additives and Intermediates segments in Q4.
Ashland Place Completes New Financing Facility for Crestone Air Partners, Air T, Inc. and Mill Road Capital
09:00am, Tuesday, 12'th Nov 2024
NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of a new facility financing the acquisiti
Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript
04:16pm, Saturday, 09'th Nov 2024
Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis -
Ashland to host live 2024 strategy update event for analysts and investors
07:00am, Friday, 08'th Nov 2024
WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company w
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
07:30am, Thursday, 07'th Nov 2024
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, D
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
06:40am, Thursday, 07'th Nov 2024
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say
08:36pm, Wednesday, 06'th Nov 2024
While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar
Ashland (ASH) Q4 Earnings Lag Estimates
08:16pm, Wednesday, 06'th Nov 2024
Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago.
ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to addr
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to addr
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia ver
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
04:01pm, Tuesday, 05'th Nov 2024
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th Americ
Media Release COPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (N
Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
10:20am, Tuesday, 05'th Nov 2024
Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
